WHO Introduces New Regulatory Path to Speed Access to Safe Medical Devices

GENEVA — The World Health Organization has published its first interim list of recognised regulatory authorities for medical devices, creating a new pathway intended to support faster access to safe and quality-assured products.

The list identifies transitional WHO Listed Authorities, known as tWLAs, that have demonstrated established regulatory performance in overseeing medical devices. The arrangement will remain in place while WHO finalises its full evaluation system for permanent listed-authority status.

Medical devices include products ranging from syringes and diagnostic tests to pacemakers, implants, imaging systems and other specialised technologies. Regulators are responsible for assessing whether these products meet appropriate standards for quality, safety and performance before they reach patients.

The complexity of modern medical technology can place significant demands on regulatory agencies. Countries with limited specialist capacity may struggle to repeat detailed assessments already completed by experienced authorities.

Regulatory reliance allows one authority to consider or use the work of another trusted regulator while retaining responsibility for its own national decision. This can reduce duplication, improve efficiency and help patients gain access to essential products more quickly.

The interim arrangement replaces the older concept of Stringent Regulatory Authorities with a more transparent, performance-based WHO framework. Authorities on the transitional list must complete the full WHO evaluation process before receiving permanent status.

The approach could be particularly valuable during public-health emergencies, when rapid access to reliable diagnostic tests and medical equipment is essential. It may also help smaller regulatory systems focus their limited resources on local surveillance, inspections and products requiring additional national review.

Reliance does not mean automatic acceptance. National authorities must still consider local law, health-system requirements, population needs, supply conditions and post-market safety information.

The WHO framework is intended to strengthen cooperation between regulators and create clearer reference points for countries deciding whose assessments they can trust.

Its success will depend on transparency, conflict-of-interest safeguards, the quality of shared information and continued monitoring after products enter the market.